These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25440735)

  • 1. Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description.
    Pina-Camacho L; Díaz-Caneja CM; Saiz PA; Bobes J; Corripio I; Grasa E; Rodriguez-Jimenez R; Fernández M; Sanjuán J; García-López A; Tapia-Casellas C; Álvarez-Blázquez M; Fraguas D; Mitjans M; Arias B; Arango C
    Rev Psiquiatr Salud Ment; 2014; 7(4):166-78. PubMed ID: 25440735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children.
    Devlin AM; Panagiotopoulos C
    Pharmacogenomics; 2015; 16(9):981-96. PubMed ID: 26107755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naïve French Canadian patients.
    Roy G; Bedard A; Desmarais PA; Jourdain F; Allen S; Michaud D; Ben Amor L
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):479-87. PubMed ID: 21186966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
    Pérez-Iglesias R; Martínez-García O; Pardo-Garcia G; Amado JA; Garcia-Unzueta MT; Tabares-Seisdedos R; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):41-51. PubMed ID: 24103107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances.
    Kao AC; Rojnic Kuzman M; Tiwari AK; Zivkovic MV; Chowdhury NI; Medved V; Kekin I; Zai CC; Lieberman JA; Meltzer HY; Bozina T; Bozina N; Kennedy JL; Sertic J; Müller DJ
    J Psychiatr Res; 2014 Jul; 54():36-42. PubMed ID: 24725652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
    Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
    Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients.
    Delacrétaz A; Glatard A; Dubath C; Gholam-Rezaee M; Sanchez-Mut JV; Gräff J; von Gunten A; Conus P; Eap CB
    Clin Epigenetics; 2019 Dec; 11(1):198. PubMed ID: 31878957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?
    Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM
    Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-related weight gain and metabolic complications in children with mental health disorders: potential role for lifestyle interventions.
    Wiedeman AM; Panagiotopoulos C; Devlin AM
    Appl Physiol Nutr Metab; 2021 Mar; 46(3):193-204. PubMed ID: 33226841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study.
    van Winkel R; Moons T; Peerbooms O; Rutten B; Peuskens J; Claes S; van Os J; De Hert M
    Int Clin Psychopharmacol; 2010 Sep; 25(5):270-6. PubMed ID: 20523222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain.
    Czerwensky F; Leucht S; Steimer W
    J Clin Psychopharmacol; 2013 Feb; 33(1):74-9. PubMed ID: 23277235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.
    Vandenberghe F; Gholam-Rezaee M; Saigí-Morgui N; Delacrétaz A; Choong E; Solida-Tozzi A; Kolly S; Thonney J; Gallo SF; Hedjal A; Ambresin AE; von Gunten A; Conus P; Eap CB
    J Clin Psychiatry; 2015 Nov; 76(11):e1417-23. PubMed ID: 26646038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology.
    Rojo LE; Gaspar PA; Silva H; Risco L; Arena P; Cubillos-Robles K; Jara B
    Pharmacol Res; 2015 Nov; 101():74-85. PubMed ID: 26218604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathophysiology of metabolic effects of antipsychotic medications.
    Ballon JS; Pajvani U; Freyberg Z; Leibel RL; Lieberman JA
    Trends Endocrinol Metab; 2014 Nov; 25(11):593-600. PubMed ID: 25190097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
    Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL
    J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics.
    de Hoogd S; Overbeek WA; Heerdink ER; Correll CU; de Graeff ER; Staal WG
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):166-73. PubMed ID: 22506734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia.
    Atti AR; Ferrari Gozzi B; Zuliani G; Bernabei V; Scudellari P; Berardi D; De Ronchi D; Tarricone I; Menchetti M
    Int Psychogeriatr; 2014 Jan; 26(1):19-37. PubMed ID: 24103643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy.
    de Leon J; Diaz FJ
    Schizophr Res; 2007 Nov; 96(1-3):185-97. PubMed ID: 17618085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies for predicting side effects from second generation antipsychotics in youth.
    Brown JT; Campo-Soria C; Bishop JR
    Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):655-664. PubMed ID: 33896324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.